The diagnostic accuracy of serum microRNAs in detection of cervical cancer: a systematic review protocol.
The diagnostic accuracy of serum microRNAs in detection of cervical cancer: a systematic review protocol.
复制标题
DOI：
10.1186/s41512-023-00142-4
复制
发表时间：
2023-01-31
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
宫颈癌仍然是世界范围内的公共卫生问题，特别是在撒哈拉以南非洲地区。及时筛查和诊断以实现早期发现和干预存在挑战。因此，对宫颈癌和宫颈上皮内瘤变的研究表明需要包括microRNA技术在内的新诊断方法。与正常状态相比，血浆/血清中的 microRNA 水平升高或降低，并且其检测宫颈肿瘤的诊断准确性尚未经过严格评估，在乌干达等资源匮乏的地区更是如此。因此，本系统评价的目的是评估血清 microRNA 在宫颈癌检测中的诊断准确性。我们将按照系统审查和荟萃分析协议的首选报告项目 (PRISMA-P) 声明进行系统审查。我们将搜索 MEDLINE/PubMed、Web of Science、Embase 和 CINAHL 中的所有文章以及 2012 年至 2022 年的灰色文献。我们的结果将是每个 microRNA 或 microRNA panel 的敏感性、特异性、阴性预测值、阳性预测值或曲线下面积（Nagamitsu 等人，Mol Clin Oncol 5:189-94, 2016）。我们将使用诊断准确性研究的质量评估（Whiting et al, Ann Intern Med 155:529-36, 2011）工具来评估纳入研究的偏倚风险。我们的结果将根据诊断测试准确性研究的系统评价和荟萃分析的首选报告项目 (PRISMA-DTA) 进行报告。我们将在流程图中总结研究，然后使用结构化叙述综合来描述它们。如果可能，我们将使用 Lehmann 模型双变量方法进行荟萃分析。本系统综述将提供有关 microRNA 在宫颈癌中的相关性的信息。这些信息将帮助政策制定者、规划者和研究人员确定哪些特定的 microRNA 可用于筛查或诊断宫颈癌。该协议已在 PROSPERO 中注册，注册号为 CRD42022313275。
Cervical cancer remains a public health problem worldwide, especially in sub-Saharan Africa. There are challenges in timely screening and diagnosis for early detection and intervention. Therefore, studies on cervical cancer and cervical intraepithelial neoplasia suggest the need for new diagnostic approaches including microRNA technology. Plasma/serum levels of microRNAs are elevated or reduced compared to the normal state and their diagnostic accuracy for detection of cervical neoplasms has not been rigorously assessed more so in low-resource settings such as Uganda. The aim of this systematic review was therefore to assess the diagnostic accuracy of serum microRNAs in detecting cervical cancer. We will perform a systematic review following the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) statement. We will search for all articles in MEDLINE/PubMed, Web of Science, Embase, and CINAHL, as well as grey literature from 2012 to 2022. Our outcomes will be sensitivity, specificity, negative predictive values, positive predictive values or area under the curve (Nagamitsu et al, Mol Clin Oncol 5:189-94, 2016) for each microRNA or microRNA panel. We will use the quality assessment of diagnostic accuracy studies (Whiting et al, Ann Intern Med 155:529-36, 2011) tool to assess the risk of bias of included studies. Our results will be reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis for Diagnostic Test Accuracy studies (PRISMA-DTA). We will summarise studies in a flow chart and then describe them using a structured narrative synthesis. If possible, we shall use the Lehmann model bivariate approach for the meta analysis This systematic review will provide information on the relevance of microRNAs in cervical cancer. This information will help policy makers, planners and researchers in determining which particular microRNAs could be employed to screen or diagnose cancer of the cervix. This protocol has been registered in PROSPERO under registration number CRD42022313275.
登录
查看更多内容
DOI：
10.1136/bmj.b2535
发表时间：
2009-07-21
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group
影响因子：
3.4
作者：
Rao, Qunxian;Zhou, Hui;Lin, Zhongqiu
通讯作者：
Lin, Zhongqiu
Stard 2015：用于报告诊断准确性研究的基本项目的更新列表。
DOI：
10.1136/bmj.h5527
发表时间：
2015-10-28
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Bossuyt PM;Reitsma JB;Bruns DE;Gatsonis CA;Glasziou PP;Irwig L;Lijmer JG;Moher D;Rennie D;de Vet HC;Kressel HY;Rifai N;Golub RM;Altman DG;Hooft L;Korevaar DA;Cohen JF;STARD Group
通讯作者：
STARD Group
影响因子：
3.7
作者：
Pereira PM;Marques JP;Soares AR;Carreto L;Santos MA
通讯作者：
Santos MA
影响因子：
3.8
作者：
Luo, Min;Shen, Dongxiang;Wang, Wei
通讯作者：
Wang, Wei